In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a GlaxoSmithKline Brand 1 of Digoxin Drug Master File in Korea (GlaxoSmithKline Brand 1 of Digoxin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of GlaxoSmithKline Brand 1 of Digoxin. The MFDS reviews the GlaxoSmithKline Brand 1 of Digoxin KDMF as part of the drug registration process and uses the information provided in the GlaxoSmithKline Brand 1 of Digoxin KDMF to evaluate the safety and efficacy of the drug.
After submitting a GlaxoSmithKline Brand 1 of Digoxin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their GlaxoSmithKline Brand 1 of Digoxin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of GlaxoSmithKline Brand 1 of Digoxin suppliers with KDMF on PharmaCompass.